Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > full enrollment maybe by now ?

<< Previous

Bullboard Posts

Next >>

Comment by talisman47on Oct 19, 2020 7:00pm

151 Views

Post# 31745539

RE:RE:RE:full enrollment maybe by now ?

I thought that once a patient was enrolled the trial period of 2 weeks started, after that the time to analyse the data and finally report results. My suggestion was that they have enrolled 150 by now and the last enrollees are in the 2 week trial period now which means trial complete by end of October and results could come out in November some time.

That's my guess....

<< Previous

Bullboard Posts

Next >>

Morning Market Outlook for Nov. 7, 2024